Amgen to Use BioWisdom's Sofia Software | GenomeWeb
NEW YORK (GenomeWeb News) – Pharmaceutical company Amgen has signed a multi-year license agreement to use BioWisdom’s knowledge network software, BioWisdom said today.
 
BioWisdom’s Sofia software is used to format large amounts of complex data that drug developers generate in their research. The Cambridge, UK-based firm said the software creates “Intelligence Networks, a unique format of assertional metadata that liberates knowledge from structured and unstructured data, regardless of its original format.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.